



•Red : important

•Black : in male / female slides

•Pink : in female's slides only

•Blue : in male's slides only

•Green : Dr's notes

•Grey: Extra information, explanation

Editing File




LECTURE 5: DRUGS IN GOUT

NOTE:

In this lecture anything that's written in red or green is the <u>female's</u> Dr. notes Anything written in <u>purple</u> is the <u>male's</u> Dr. notes


OBJECTIVES:

- Identify the mechanism of action of drugs used for treatment of Gout.
- Classify drugs used for treatment of Gout.
- Outline the stages of Gout and the therapeutic objectives in each stage.
- Describe drug and non drug treatment of gout.
- Study in details the pharmacology of drugs used for treatment of gout.



cytotoxic agents, this causes the release of purines such as Adenine and Guanine, the end product of their catabolism is uric acid).

Untreated Gout leads to:



Epidemiology :

Gout was historically known as "the disease of kings" or "rich man's disease."

- Prevalence of hyperuricemia 5% . Not all of them will develop the disease.
 - Prevalence of gout 0.2%
 - Male to female ratio 10:1

Pathophysiology :


gout is due to:

1- overproduction of uric acid (Uricostatic) 2- underexcretion (Uriocosuric)
 •Urate crystals are initially phagocytosed by synoviocytes, which then release prostaglandins, lysosomal enzymes, and interleukin-1


(inflammatory mediators) which attracts and activates polymorphonuclear leukocytes (PMN) and mononuclear phagocytes (MNP) (macrophages). This is why we use NSAIDs.

• Attracted by these chemotactic mediators, polymorphonuclear leukocytes and mononuclear phagocytes migrate into the joint space and amplify the ongoing inflammatory process.

• In the later phases of the attack, increased numbers of mononuclear phagocytes (macrophages) appear, ingest the urate crystals, and release more inflammatory mediators



Treatment of Gout:



What is the management of gout? or any disease.

1- Non-pharmacological treatment first 2- pharmacological treatment second

Aim of Pharmacotherapy:

Most therapeutic strategies for gout involve **lowering the uric acid level below the saturation point (<6 mg/dL)**, thus preventing the deposition of urate **crystals**. This can be accomplished by: (how these drugs work)

1- Interfering with uric acid synthesis with **allopurinol**, **Febuxostat**.

- 2- increasing uric acid excretion with probenecid or sulfinpyrazone.
- 3- Inhibiting leukocyte entry into the affected joint with **colchicine**.
- 4- Administration of NSAIDs. such as naproxen and ibuprofen in HIGH doses (Anti-inflammatory and analgesic effects)

"Classification of drugs", it's important to know the drug and the

group it belongs to

Treatment of Acute Gout:


| NSAIDs | To stop inflammation The most commonly used first-line treatment.(because they relieve pain) Head-to-head studies show few differences between drugs. (Drugs of this class are similar). Full Doses of NSAIDs should be initiated immediately and tapered after resolution of symptoms. (we do not start with small doses) (keep in mind that one of the ADRs of aspirin is acute gouty arthritis when given in low doses) | |
|-----------------|---|--|
| Contraindicated | 1- GI ulcer. 2- Bleeding or perforation. 3- Renal insufficiency. 4- Heart Failure. 5- Use of oral anticoagulants. (Increases bleeding). *Recall Lecture 2 NSAIDs | |

Cont.

| Steroids (Stronger than NSAIDs) | Corticosteroids are a good alternative where NSAIDs and colchicine cannot be used or in refractory cases. (Resistance case) Studies showed equal efficacy between corticosteroids and NSAIDs, with no reported side-effects with <u>short-term</u> use of corticosteroids. |
|------------------------------------|---|
| Uses | In elderly people, patients with with liver or hepatic impairment, IHD (Ischemic heart disease), PUD (Peptic ulcer disease), Hypersensitivity to NSAIDs. |
| Route of Administration | Intra articularly (preferred route if one or two joints are affected). long use causes joint damage and increased risk of infections leading to severe arthritis. Orally. Intramuscularly or intravenously. |

Cont.


| Colchicine (Very important) | Origin: Alkaloid obtained from autumn crocus (flowering plant). The effect: Minimal effect on uric acid synthesis, excretion & is not analgesic. |
|---|---|
| Mechanism What is the Main mechanism ? Microtubules inhibitor (Antimitotic drug) | Binds to microtubules in neutrophils. Inhibits cell division by:(Mitosis) Inhibits chemotactic factors. Inhibits inflamosomes & IL-1 production. (inflamosomes are inflammatory proteins) Colchicine relieves a painful gouty attack by going to work right in the joint (localized). It can have you running smoothly again. |
| Pharmacokinetic | Route of Administration: orally.(I.V causes diarrhea,bone marrow suppression increase) Absorption: rapidly absorbed from the GI tract. Half-life: reaches peak plasma levels within 2 hours. Recycling: in the bile. (Enterohepatic circulation). Excretion: unchanged in the faeces or urine. Should be avoided in: patients with a creatinine clearance of less than 50 mL/min. (Renal diseases patients). |
| Clinical Uses | Treatment of gout flares.(Acute) Prophylaxis (Prevention) of gout flares. (In between attacks) Treatment of Mediterranean fever. |
| Side Effects important | Abdominal: Diarrhea (sometimes severe and bloody, the patient stops taking the drug), Nausea, Vomiting, Abdominal Cramps, Dehydration. Immune: Bone marrow depression. (may cause hair fall like in chemotherapy)."because they are anti-mitotic drugs" Cardiac (large doses): Cardiac toxicity, arrhythmia, Vascular collapse, Hepatotoxicity, alopecia. |



Uric acid synthesis inhibitors: Allopurinol, Febuxostat

| Mechanism of Action | ● Inhibit Xanthine oxidase. Hypoxanthine → Xanthine → Uric acid | | |
|---|--|--|--|
| | Allopurinol not active is metabolized by xanthine oxidase into alloxanthine (oxypurinol) which is pharmacologically active Xanthine oxidase (Xanthine oxidase) Xanthine oxidase Xanthine oxidase Vanthine oxidase Vanthine oxidase Vanthine oxidase Vanthine oxidase Vanthine oxidase | | |
| P.K Pharmacokinetics | Absorption 70% Protein Binding negligible 5% Hepatic metabolism, 70% converted to active metabolite (Oxypurinol) which is eliminated unchanged in the urine. | | |
| ADRS These side effects are due to the active metabolite Alloxanthine (Oxypurinol) | 1-Diarrhea, nausea, abnormal liver tests. 2-Acute attacks of gout. explained in the green note below 3-Fever, rash, *toxic epidermal necrolysis (Severe ADRS), hepatotoxicity, marrow suppression vasculitis. 4-DRESS syndrome (Drug reaction, Eosinophilia, Systemic Symptoms). 5-20% mortality rate. 6- Allopurinol hypersensitivity syndrome | | |
| | بداية العلاج ممكن تحصل هجمات ليش ؟ لأن آلية عمل الأدوية انها تقلل من اليوريك أسيد الليّ بالدم ف اليوريك أسيد الليّ في ال Toxic epidermal راح يحصل له mobilization ويرجع يدخل الدم من جديد فتحصل الهجمات ويرجع يدخل الدم من جديد فتحصل الهجمات | | |

| Drug | Allopurinol | Febuxostat |
|------------------|---|---|
| Clinical Uses | Management of hyperuricemia of gout. Mainly Uric acid stones or nephropathy. It is a drug of choice in patients with with both gout & ischemic heart disease Severe tophaceous deposits in tissues). Management of hyperuricemia associated with chemotherapy. Prevention of recurrent calcium oxalate kidney stones. (when cells are destroyed, lots of purine is diffused). | Indicated for the management of hyperuricemia in patients with gout (as it reduces serum uric acid levels). Chemically distinct from allopurinol (non purine). Can be used in patients with renal disease. Oral specific xanthine oxidase inhibitor. More specific than allopurinol |
| P.K | Metabolism: it is metabolized by xanthine oxidase into alloxanthin which is pharmacologically active (The active metabolite inhibits the enzyme). Absorption 70% Protein Binding negligible 5% Hepatic metabolism, 70% converted to active metabolite(Oxypurinol) which is eliminated unchanged in the urine. | Route of administration : Given orally once daily. Absorption: well absorbed(85%). Metabolism: Metabolized in liver, mainly conjugated to glucuronic acid Protein BInding: 99%. Half life: (Girls slide:8 hrs, Boys slide :4-18 hrs) Given to patients who do not tolerate allopurinol. High dose of febuxostat have a lesser effect than the lowest dose of allopurinol. |
| ADRs | The side effects are due to the active metabolite which are: Allopurinol Hypersensitivity Syndrome Toxic Epidermal Necrolysis DRESS Syndrome (Drug Reaction Eosinophilia Systemic Symptoms) 20% mortality rate. Fever, rash, marrow suppression, diarrhea, nausea, abnormal liver tests & vasculitis, acute gout attacks and hepatotoxicity | Increases number of gout attacks the first few months of treatment. Increases level of liver enzymes. Nausea, diarrhea. Numbness of arm or leg. Headache |



TYPES OF URICOSURIC DRUGS

| Drugs | Probenecid | Sulfinpyrazone | |
|---------------------------------|---|--|--|
| Features | ADRS (side effect): •Exacerbation of acute attack •Risk of uric acid stone • GIT upset • Allergic rash. | Can aggravate peptic ulcer disease. Aspirin reduces efficacy of sulfinpyrazone. Enhances the action of certain anti-diabetic drugs.Lower blood glucose | |
| MOA (Mechanism of action) | Probenecid inhibits Urate Transporters (URAT) in the apical membrane of the proximal tubule It also inhibits organic acid transporter(OAT) → ↑ plasma concentration of penicillin | Sulfinpyrazone inhibits URAT1 & OAT4. (Organic acid transporter 4) (responsible for reabsorption of uric acid) | |
| | Blood Increased Basea Uric acid Pencillin Cephalosporins Methotrexate Probenecid Aspirin Dasolateral | Basolateral membrane + OATI + OATI + Uric acid + URATI Probenecid Benzbromarone epithelial cell + GLIT9 - Uric acid + OAT4 Probenecid Benzbromarone Sulfinpyrazone + GLIT9 - Uric acid + OAT4 Probenecid Benzbromarone Sulfinpyrazone + GLIT9 - Uric acid + OAT4 Probenecid Benzbromarone Sulfinpyrazone + GLIT9 - Uric acid + OAT4 Probenecid Benzbromarone - GLIT9 - Uric acid - OAT4 - OAT4 - Probenecid - OAT4 - | |
| Effect | 1-Moderately effective. | | |

| | Pegloticase | | | |
|-----------------------------------|---|--|--|--|
| Mechanisms | A uric acid specific enzyme which is a recombinant modified mammalian uricase enzyme through genetic engineering Enzymatically converts uric acid to <u>allantoin</u>, which is more soluble and readily excreted in the urine. کأنها الن تلينين فتلين وتصير سايلة وتطلع من الجسم | | | |
| Clinical use | Used for the treatment of chronic gout in adult patients refractory to conventional therapy. Expensive therapy | | | |
| P.K (Pharmacokinetics) | Route of administration: IV peak decline in uric acid level within 24-72 hours (Rapid decrease, and this is an advantage) | | | |
| ADRS Adverse drug reactions | Infusion reactions. Fever and skin rash Anaphylaxis. Life threatening Gout flare Arthralgia (arthra: joints, algia: pain) Muscle spasm. During infusion and after it Nephrolithiasis | | | |
| | Uric Acid Uri- | | | |
| \int | Case Pegloticase | | | |
| Renal excretion | GIT Circulating excretion In excess | | | |
| | 1 | | | |
| | Tophi Urate Deposition | | | |

| SUMMARY | | | | | |
|-----------------------------|-----------------------|--|---|--|---|
| Summary table from team 437 | | | | | |
| | Nonphar- macologic | Lifestyle modifications - Loss of weight - Exercise - Diet control - Smoking cessation and avoid alcohol | | | |
| gout | | Treatment of acute | NSAIDs | First line treatment Contraindicated : heart failure | |
| eatment of gout | Pharmacological | gout | steroids | -Stronger than NSAIDs -Uses in elderly people or hypersensitivity to NSAIDs | |
| Tre | | | Colchicine | Treatment of Mediterranean (inflammatory) fever | |
| | | Prevention of recurrent | Inhibition of uric acid synthesis | Allopurinol drug of choice in patients with both gout & ischemic heart disease. | Febuxostate Patients with renal disease |
| | | attacks | Uricosuric drugs | Probenecid ↑plasma concentration of penicillin. | Sulfinpyrazone inhibits URAT1 & OAT4. |
| | | | MamalianPegloticase : convert urauricaseallantoin | | nvert urate to |

QUIZ

MCQs

1-Which of the following causes the inflammatory process in Gout?

A-Deposits of Sodium Urate Crystals B-High serum Uric acid C-Cytokines

2-A 50 years old man came to the ER complaining from severe pain in his toes joints with hotness on them. Blood sample was taken from him and it revealed high uric acid with creatine clearance rate of 23 mL/min. Which of the following should be avoided in treating his Gout?

A-NSAIDs B-Colchicine

C-Febuxostat

3-Allopurinol is metabolized into Alloxanthin by

A-Aspirin B-Xanthine oxidase C-Pegloticase

4-Jamal is a 35 years old man with known history of Gout was diagnosed with bacterial infection and was prescribed penicillin. Which drug of Gout his doctor must stop it in this case due to interaction ?

A-Probenecid B-Febuxostat

C-Steroids

5-If a Gout patient has ischemic heart disease, what is the drug of choice?

- A-Pegloticase
- **B-Allopurinol**
- C-Colchicine





A- What are the stages of Gout?

Four distinct stages: a) asymptomatic hyperuricemia b) acute intermittent gout c)Intercritical stage d) chronic gout

B-How to manage each stage?

Asymptotic: Life style modification Acute: terminate the attack Intercritical: Prevent the recurrent attacks Chronic: prevent complication and lower serum uric acid

C-In Gout we have acute treatment and prophylactic therapy. According to the previous statement, answer the following:

• Write Colchicine mechanism of action and clinical uses: Slide 6 in Colchicine part.

• Mention one class that is used a preventive therapy with two ADRs:

Any class with its ADRs

D- Give a short answer about the metabolism of allopurinol.

It is metabolized by xanthine oxidase into alloxanthin which is pharmacologically active.



GOOD LUCK

Team Leaders:

Nouf Alshammari

Zyad Aldosari

Team Members:

Alwaleed Alsaleh Talal Abozaid Muhannad Makkawi

Sources: Team 435 Team 437